Related Experiment Video
Updated: Jul 18, 2026
07:01
Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors
Published on: March 1, 2020
CD24 expression is a poor prognostic marker in endometrial carcinoma
1Department of Pathology, Faculty of Medicine, Süleyman Demirel University, Isparta, Turkey.
European Journal of Gynaecological Oncology
|December 5, 2006
Summary
CD24 expression in endometrial cancer indicates a more aggressive tumor biology. This finding suggests CD24 may serve as a new prognostic marker for endometrial cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- CD24, a cell adhesion molecule, plays a role in tumor progression.
- CD24 expression is linked to prognosis in various solid tumors.
Purpose of the Study:
- To investigate the prognostic significance of CD24 in endometrial cancer.
- To determine if CD24 expression correlates with clinical parameters in endometrial cancer.
Main Methods:
- Immunohistochemistry was used to detect CD24 expression in 44 endometrial carcinoma tissues.
- Cytoplasmic and membranous CD24 immunoreactivity were semiquantitatively scored.
- Fisher's exact test was employed for statistical analysis.
Main Results:
- CD24 expression was observed in 77.3% of endometrial cancer cases.
- CD24 expression showed a significant association with International Federation of Gynecology and Obstetrics (FIGO) grade.
- CD24 expression was also significantly correlated with nodal status.
Conclusions:
- CD24 expression may serve as a novel marker for aggressive endometrial cancer biology.
- The findings support the role of CD24 in endometrial cancer progression.
- CD24 is frequently upregulated in endometrial cancer, highlighting its importance.